版本:
中国

BRIEF-Merrimack completes ONIVYDE sale to Ipsen

April 3 Merrimack Pharmaceuticals Inc:

* Merrimack launches as new, refocused research & clinical development company with resources to advance prioritized lead pipeline candidates MM-121, MM-141 and MM-310

* Plans to return $140 million to stockholders through special cash dividend

* Merrimack received $575 million in cash upon closing Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐